Manuscript no. HAEMATOL/2012/068510 entitled “Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas”

Authors: Esperanza Martín-Sánchez, Socorro M. Rodríguez-Pinilla, Margarita Sánchez-Beato, Luis Lombardía, Beatriz Domínguez-González, Diana Romero, Lina Odqvist, Pablo García-Sanz, Magdalena B. Wozniak, Guido Kurz, Carmen Blanco-Aparicio, Manuela Mollejo, Francisco Javier Alves, Javier Menárguez, Fernando González-Palacios, José Luis Rodríguez-Peralto, Pablo L. Ortiz-Romero, Juan F. García, James R. Bischoff and Miguel A. Piris

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Esperanza Martín-Sánchez, Molecular Pathology Programme, Spanish National Cancer Research Centre (Madrid, Spain), emartins@cnio.es
   • Miguel A Piris, Molecular Pathology Programme, Spanish National Cancer Research Centre (Madrid, Spain) and Department of Pathology, Hospital Universitario Marqués de Valdecilla - IFIMAV (Santander, Spain), mapiris@humv.es

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Miguel A Piris

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
   • Esperanza Martín-Sánchez was the responsible for the majority of experiments, except the following ones:
   • Luis Lombardía and Diana Romero were responsible for the sequencing in PTCL cell lines.
   • Pablo García-Sanz and Juan F Garcia were responsible for the sequencing of the PIK3CD gene in PTCL cases.
   • Guido Kurz, Carmen Blanco-Aparicio and James R Bischoff were responsible for the development of the pan-PI3K inhibitor ETP-45658.
   • Manuela Mollejo, Francisco J Alves, Javier Menárguez, Fernando González-Palacios and José Luis Rodríguez-Peralto were responsible for the diagnosis, storing and providing PTCL samples.
   • Pablo L Ortiz-Romero was responsible for the diagnosis, storing and providing Sezary Syndrome patients’ and healthy donors’ samples.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
   • Esperanza Martín-Sánchez was the responsible for all the experiments and figures, in some of them in collaboration with:
   • Magdalena B Wozniak was the responsible for a portion of the analysis of the PTCL molecular signature (Figure 1A).
   • Lina Odqvist was the responsible for the quantitative PCR of PIK3CD and PIK3CA in the samples from Sezary Syndrome patients (Figure 1D).
• Beatriz-Domínguez-González was the responsible for some Western blots in Figure 4B.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
• Esperanza Martin-Sanchez was the responsible for writing the manuscript.
• Socorro M Rodríguez-Pinilla, Margarita Sánchez-Beato, Juan F García and Miguel A Piris were the responsible for revising the manuscript.

6) Contributors Listed in Acknowledgments:
• Francisco X Real: for his contribution to the scientific discussion.
• The Spanish National Tumour Bank Network: for their help in collecting and managing the samples from the hospitals.
• Asociación Española Contra el Cáncer, Fondo de Investigaciones Sanitarias (PI051623, PI052800 and PI080856), RTICC (RD06/0020/0107) and Ministerio de Ciencia e Innovación (SAF2008-0387-1): for general funding.
• The Department of Education, Universities and Research of the Basque Government (BFI08.207): for Esperanza Martin-Sánchez’s funding.
• The Contract Miguel Servet from Fondo de Investigaciones Sanitarias (CP11/00018): for Margarita Sánchez-Beato’s funding.